At Balancial we use quality systems, regulatory procedures, and a data-based mindset from the pharmaceutical industry

Message from the CEO

Bo Tandrup

CEO, M.Sc. Pharmaceutical Sciences

Medicinal cannabis is a controversial subject. We acknowledge that Doctors are sceptical towards non-authorised medicines with inadequate knowledge of effects and side-effects, but a few important facts should be emphasized.

Firstly, although not exhaustive, we do have some clinical data to support the use of medicinal cannabis. The Danish Medicines Agency has prepared guidelines for doctors based on extensive literature searches, assessments of the review of scientific evidence from the National Academy of Sciences (USA, 2017), evaluation of cannabis schemes in other countries and evaluation of the data leading to previous licensing of cannabis-containing medicines in Europe and the USA.

Secondly, medicinal cannabis is not a substitute for authorised medicines. It is to be tried only if the patient has not benefitted from the treatment with relevant authorised medicine.

Finally, the intention with the Danish pilot programme is to provide a better basis to assess the use of medicinal cannabis. Therefore, quality assured medicinal cannabis products should be made available as long as such products are admitted or approved by the Danish Medicines Agency.

At Balancial we are pharmaceutical industry professionals. We confer with doctors from various clinical fields, select products based on their recommendations and assure that they conform with any and all regulatory requirements before we make them available on the Danish market.

‍Balancial’s products should be considered only for the following indications that are supported by some evidence:

• Painful spasms caused by multiple sclerosis
• Painful spasms caused by spinal cord damage
  
• Nausea after chemotherapy
  
• Neuropathic pain, i.e. pain due to a disease of the brain, spinal cord or nerves